Analysis Tools
mortality/aging
|
• mice become moribund by 18 to 22 months of age
|
hematopoietic system
|
• progressive starting at 5 to 6 months of age
• 6 to 7 times on necropsy
|
|
• at 6 months, mice develop lympho- and myeloproliferative syndrome compared with wild-type mice
• however, mice exhibit normal lymphoid cell numbers at 6 to 8 weeks and disease is not present in mice treated with an IFNgamma blocker
|
|
• at 6 months, mice develop lympho- and myeloproliferative syndrome compared with wild-type mice
(J:167922)
• however, mice exhibit normal myeloid cell numbers at 6 to 8 weeks and disease is not present in mice treated with an IFNgamma blocker
(J:167922)
• chronic myeloproliferation and myelofibrosis in the bone marrow
(J:173230)
|
|
• in the spleen
|
|
• by 18 to 22 months, mice develop end-stage fibrosis or a hypercellular bone marrow and pale bone marrow unlike wild-type mice
|
|
• by 18 to 22 months
|
|
• in the periphery but not thymus
• not rescued by treatment with an IFNgamma blocker
|
|
• increased proliferation of T regulatory cells
• impaired suppressive T regulatory cell function (measured by Th1 cytokine production)
|
immune system
|
• progressive starting at 5 to 6 months of age
• 6 to 7 times on necropsy
|
|
• at 6 months, mice develop lympho- and myeloproliferative syndrome compared with wild-type mice
• however, mice exhibit normal lymphoid cell numbers at 6 to 8 weeks and disease is not present in mice treated with an IFNgamma blocker
|
|
• at 6 months, mice develop lympho- and myeloproliferative syndrome compared with wild-type mice
(J:167922)
• however, mice exhibit normal myeloid cell numbers at 6 to 8 weeks and disease is not present in mice treated with an IFNgamma blocker
(J:167922)
• chronic myeloproliferation and myelofibrosis in the bone marrow
(J:173230)
|
|
• in the periphery but not thymus
• not rescued by treatment with an IFNgamma blocker
|
|
• increased proliferation of T regulatory cells
• impaired suppressive T regulatory cell function (measured by Th1 cytokine production)
|
|
• from T cells upon activation under nonpolarizing Th0 conditions
|
neoplasm
|
• some mice develop lymphomas of B cell or mixed T and B cell lineage in the cervical lymph node, gastrointestinal tract, liver and kidney
|
|
• some mice develop lymphomas of B cell or mixed T and B cell lineage in the cervical lymph node, gastrointestinal tract, liver and kidney
• some mice develop high-grade diffuse large B cell lymphoma with apoptotic bodies and atypical mitosis
|
|
• low-grade in some mice
|
|
• in the spleen and occasionally in the liver and kidney
• myeloid tumors are transplantable into immunocompromised mice
|
|
• spleen tumors with myeloid sarcoma histology in many mice
|
skeleton
|
• myelofibrosis in the bone marrow
|
growth/size/body
|
• progressive starting at 5 to 6 months of age
• 6 to 7 times on necropsy
|
endocrine/exocrine glands
|
• some mice develop lymphomas of B cell or mixed T and B cell lineage in the cervical lymph node, gastrointestinal tract, liver and kidney
|
